What podcasts say about Steve Usdin

Every statement, with the speaker, the exact quote and the moment it was said.

What Steve Usdin has said on podcasts

11 statements · 1 positive · 5 negative · 5 neutral

on U.S.-China biotech co-development dealsNegativeOct 6, 2026· BioCentury This Week
More large biotech co-development deals may produce more restrictive Treasury rules.
“that's likely to fuel a more restrictive rules when we do see Treasury putting out its rules on how it's going to incorporate biotech into coins.”
Listen at 7:40
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Beam Therapeutics lawsuit against YoltecNeutralOct 6, 2026· BioCentury This Week
Beam Therapeutics filed a trade-secret lawsuit against Yoltec.
“Beam Therapeutics filed suit on September 25 in the U.S. District Court for the District of Massachusetts.”
Listen at 11:49
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Beam-Yoltec trade-secret trialNeutralOct 6, 2026· BioCentury This Week
A trial outcome would depend heavily on explaining complex science to jurors.
“the outcome of a trial, again, if it does go to trial, is going to hinge a lot on the two sides' ability to make very complex scientific information accessible to jurors.”
Listen at 15:24
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Beam Therapeutics-Prime Medicine arbitrationPositiveOct 6, 2026· BioCentury This Week
Prime Medicine prevailed in its arbitration with Beam.
“Prime prevailed in that arbitration.”
Listen at 18:21
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Globe modelNegativeOct 6, 2026· BioCentury This Week
Globe projected savings have fallen to approximately $440 million.
“That has shriveled to about $440 million.”
Listen at 20:47
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Globe modelNegativeOct 6, 2026· BioCentury This Week
Globe will likely face a court challenge.
“I think that Globe is going to be challenged in court”
Listen at 21:11
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Globe model precedentNeutralOct 6, 2026· BioCentury This Week
Globe’s policy precedent matters more than its financial savings.
“The precedent really does matter more than the money here.”
Listen at 21:42
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on International reference pricingNegativeOct 6, 2026· BioCentury This Week
Democrats may pursue international reference pricing through the IRA and other programs.
“they're going to try to do it through the IRA, through the Medicare drug price negotiation program, and in other ways.”
Listen at 22:34
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Presidential pharmaceutical price negotiationsNeutralOct 6, 2026· BioCentury This Week
Presidential negotiation of drug prices will outlast the Globe model.
“that's a precedent that's going to outlast whatever happens with the Globe model”
Listen at 22:59
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Globe and Guard modelsNeutralOct 6, 2026· BioCentury This Week
Globe and Guard are scheduled to begin January 1.
“both Globe and Guard are going to start January 1.”
Listen at 23:46
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
on Globe and Guard modelsNegativeOct 6, 2026· BioCentury This Week
Litigation challenging Globe and Guard is quite likely.
“I think litigation is quite likely.”
Listen at 23:54
Open the episode · Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.